Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of LY2216684 adjunctive to SSRI in major depressive disorder partial responders
2010-020726-18Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of edivoxetine in major depressive disorder (MDD), sponsored by Eli Lilly and Company. Primary endpoints: Study Period II endpoint timing, Long-term safety and tolerability and 11 more. Started Oct 2010; status: completed.
02
Drugs
edivoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-020726-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020726-18.